Assessment of the Safety & Tolerability of Long-term Use of Patented Transdermal Patches in Healthy Adults.

Vitamin D Clinical Trial

Official title:

A Parallel Pilot Study to Assess the Safety and Tolerability of Long-term Use of Patented Transdermal Patches in Healthy Adults.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04851990
• Other study ID #: AFCRO-135
• Status: Completed
• Phase: N/A
• Start date: April 19, 2021
• Est. completion date: July 20, 2021

Study information

• Verified date: August 2021
• Source: Horopito Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a pilot study to assess the safety and tolerability of long-term use of patented transdermal vitamin D patches in healthy adults.

Description:

A randomised, parallel, pilot study to assess the safety and tolerability of long-term use of patented transdermal patches in healthy adults. The study consists of 4 on-site visits: the Screening Visit (Visit 1, Week -2), the Baseline Visit (Visit 2, Week 0), Visit 3 (Week 4), and the End of Intervention Visit (Week 8).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: July 20, 2021
• Est. primary completion date: July 16, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• 1. Individuals who are willing to participate in the study and comply with its procedures.

2. Individuals who are able to give written informed consent. 3. Individuals between 18-70 years old. 4. Has a BMI between 18-32 kg/m2 (inclusive). 5. Individuals who are willing to not undertake overseas travel for the duration of the study or engage in excessive sun-exposure or use of sun lamps or tanning beds for the duration of the study.

6. Individuals who are willing to maintain their current diet and not change supplement usage for the duration of the study.

7. Individuals who are willing to self-administer finger prick sampling. 8. Individuals who are willing to avoid strenuous exercise or exposing the patch to external sources of direct heat e.g., heating pads or electric blankets, heat lamps, saunas, hot tubs, heated water beds, and prolonged direct sunlight, while wearing the patch.

9. Individuals willing to refrain from swimming or other sports involving immersion in water for the duration of the study.

10. Individuals who have Serum 25-Hydroxyvitamin D concentration of =15 nmol/L and =100 nmol/L at screening.

Exclusion Criteria:

• 1. Are less than 18 or greater than 70 years old. 2. Participants who are pregnant, breastfeeding, or wish to become pregnant during the study.

3. Individuals currently of childbearing potential, but not using an effective method

of contraception, as outlined below:

1. Complete abstinence from intercourse two weeks prior to administration of Investigational Product, throughout the clinical trial, until the completion of follow-up procedures or for two weeks following discontinuation of the Investigational Product in cases where participant discontinues the study prematurely. (Participants utilising this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding 2 weeks when they present to the clinic for the Final Visit).

2. Has a male sexual partner who is surgically sterilised prior to the Screening Visit and is the only male sexual partner for that participant.

3. Sexual partner(s) is/are exclusively female.

4. Use of acceptable method of contraception, such as a spermicide, mechanical barrier (e.g., male condom, female diaphragm) or contraceptive pill. The participant must be using this method for at least 2 weeks prior to use of the Investigational Product and at least 1 week following the end of the study.

5. Use of any non-hormonal intrauterine device (IUD) or contraceptive implant with published data showing that the highest expected failure rate is less than 1 % per year. The participant must have the device inserted at least 2 weeks prior to the first Screening Visit, throughout the study, and 2 weeks following the end of the study.

4. Individuals who are hypersensitive to any of the components of the investigational product.

5. Individuals who have a condition affecting the integrity of the skin (e.g., psoriasis or eczema).

6. Individuals who are taking, or have taken, any prescribed or over the counter (OTC) drug and antacids, supplements, or herbal remedies in the 14 days before patch administration including any drugs known to interfere with vitamin D metabolism (e.g., steroids, orlistat, cholestyramine, phenytoin, statins, thiazide diuretics etc.). Occasional use of paracetamol up to a maximum of 2 g per day, hormone replacement therapy [HRT] or hormonal contraception are permissible.

7. Individuals who have taken calcium supplements within the previous 8 weeks. 8. Individuals who are taking vitamin D supplements greater than 10 micrograms per day.

9. Individuals with any history of or concurrent clinically significant diseases or conditions (e.g., kidney or liver dysfunction).

10. Individuals with a known history of allergy to plasters or patches. 11. Individuals who have planned major changes in lifestyle (i.e., diet, dieting, exercise level, travelling) during the duration of the study

Related Conditions & MeSH terms

• Vitamin D

Intervention

Other:
• To Better Days Large Patch
Large patch containing vitamin D & Dextrose for transdermal absorption
• To Better Days Small Patch
Small patch containing vitamin D & Dextrose for transdermal absorption

Locations

Country	Name	City	State
Ireland	Atlantia Food Clinical Trials	Cork

Sponsors (2)

Lead Sponsor	Collaborator
Horopito Limited	Atlantia Food Clinical Trials

Country where clinical trial is conducted

Ireland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants experiencing at least one treatment-emergent adverse event (TEAE) including causality, severity, and seriousness assessments.	Record number of individual participants experiencing TEAE	Baseline to week 8
Primary	Number of treatment-emergent adverse event (TEAE) including causality, severity, and seriousness assessments.	Record number of TEAE per treatment arm	Baseline to 8 weeks
Primary	Number of participants with discontinuations due to AEs or TEAEs	Record any participants discontinued due to TEAE	Baseline to 8 weeks
Primary	Change in Full Blood Count	Monitor blood safety parameters	Baseline to week 8
Primary	Change in blood lipids - total cholesterol, HDL and LDL, triglycerides mmol/l	Monitor blood safety parameters	Baseline to week 8
Primary	Change in Liver Function Tests - IU/l - alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gama-glutamyl transferase	Monitor blood safety parameters	Baseline to week 8
Primary	Change in blood glucose mmol/l	Monitor blood safety parameters	Baseline to week 8
Primary	Change in blood bilirubin mg/dl	Monitor blood safety parameters	Baseline to week 8
Primary	Change in blood calcium mg/dl	Monitor blood safety parameters	Baseline to week 8
Primary	Change in blood protein g/l - total protein, albumin & globulin	Monitor blood safety parameters	Baseline to week 8
Primary	Change in blood creatine mg/dl	Monitor blood safety parameters	Baseline to week 8
Primary	Change in blood urea mg/dl	Monitor blood safety parameters	Baseline to week 8
Primary	Change in blood uric acid mg/dl	Monitor blood safety parameters	Baseline to week 8
Primary	Change in blood electrolytes mmol/l - sodium, potassium, chloride, bicarbonate, magnesium & phosphate	Monitor blood safety parameters	Baseline to week 8
Primary	Baseline Serum Vitamin D (25-OH) nmol/l	Monitor blood safety parameters	Baseline
Primary	Change in blood pressure - systolic blood pressure (mmHg) & diastolic blood pressure (mmHg)	Monitor safety measurements	Baseline to 8 weeks
Primary	Change in heart rate (BPM)	Monitor safety measurements	Baseline to 8 weeks
Primary	Change in body temperature (°C)	Monitor safety measurements	Baseline to 8 weeks
Secondary	Change in serum vitamin D levels, measured using at-home self-administered finger prick -nmol/l	Measure change to plasma vitamin D in response to daily patch application	Baseline - 8 weeks